ResearchResearch summary
Photodynamic therapy for denture stomatitis: 2024 review
The 2024 review included 11 randomized trials; its two-trial adjunct estimate was uncertain, and a later review of overlapping trials reported a different, very-low-certainty result.
In this pathway
- Current topic
- Photodynamic therapy for denture stomatitis: 2024 reviewCurrent

Bottom line
The 2024 review included 11 randomized trials of photodynamic therapy (PDT) for denture stomatitis. Its pooled estimates did not show a clear difference between PDT alone and topical antifungal treatment, or a clear benefit from adding PDT to an antifungal. A 2026 review of an overlapping two-trial adjunct set reported a borderline day-15 result using a different effect measure, but rated the evidence very low and left important analysis questions unresolved.
Why this source matters
This review summarizes clinical trials of a defined, clinician-delivered treatment in people with denture stomatitis. It is useful historical context for that condition, but its search ended in June 2023 and a later review has reanalyzed some of the same trials. The results do not test consumer products marketed as biofilm disruptors or support broader Candida claims.
Study and population
Al-Maweri and colleagues published a PRISMA-guided systematic review and meta-analysis on January 16, 2024. They searched PubMed, Scopus, Web of Science, Google Scholar, and ProQuest through June 7, 2023, for randomized clinical trials in people with denture stomatitis. The 11 included trials were published from 2011 through 2023. The Results section reports 450 participants; the abstract reports 460, and the paper does not explain the difference. Individual trial sizes ranged from 22 to 65, and follow-up ranged from 30 to 90 days. The review did not provide one shared case definition or severity threshold for denture stomatitis.
What was tested
Eight trials compared PDT alone with a topical antifungal: nystatin in seven trials, miconazole in three, or clotrimazole paint in one. Three trials evaluated PDT added to antifungal treatment, including one three-arm trial. Eight trials contributed to at least one quantitative pool. PDT protocols differed in photosensitizer, concentration, light source and settings, number of sessions, and follow-up. The review examined fungal-count or species-prevalence outcomes and clinical signs such as pain, burning, redness, or lesion size. These trials concerned treatment delivered for denture stomatitis; they did not test supplements or other consumer products.
Results
For PDT alone versus topical antifungal at day 15, five trials included 100 people in the PDT groups and 103 in the antifungal groups. The pooled mean difference (MD) was 0.95 (95% CI −0.28 to 2.19; I²=85%; p=.13). At the end of follow-up, six trials included 115 and 118 people, respectively; MD was −0.17 (95% CI −1.33 to 0.98; p=.77). The figure reports I²=81% for this later comparison, while the Results paragraph reports 88%. The review does not resolve that discrepancy.
Across five trials reporting clinical-sign improvement, the counts were 57/103 with PDT and 54/108 with antifungal treatment. The pooled odds ratio was 1.28 (95% CI 0.72–2.29; I²=3%; p=.40). The trials did not use a harmonized definition of clinical improvement.
For adjunct PDT plus antifungal versus antifungal alone, two pooled trials included 48 participants per group. At day 15 the MD was −6.67 (95% CI −15.15 to 1.82; I²=72%; p=.12); at the end of follow-up it was −7.14 (95% CI −19.78 to 5.50; I²=97%; p=.27). Neither pooled confidence interval excludes no difference. The figure does not state an interpretable CFU unit, so these values should not be converted into one.
A later 2026 review by Tongwichian and Kessuwanrak appears to use the same two adjunct trials but reports standardized mean differences. Its day-15 estimate was −1.350 (95% CI −2.689 to −0.101; p=.048; I²=88.2%); its day-60 estimate was −1.007 (−2.553 to 0.539; p=.202; I²=92.5%). Its all-time estimate was −1.173 (−1.990 to −0.356; p=.005; I²=86.3%). The day-15 finding is borderline and comes from an alternative analysis of the same participants, not new trial data. The 2026 review rates both outcomes very low certainty, gives no group Ns in its forest plots, and does not explain how repeated time points were combined. Its all-time significance therefore does not establish a reproducible adjunct effect or patient benefit.
Applicability
These findings concern photodynamic therapy used by clinicians in randomized trials for diagnosed denture stomatitis. They do not establish a standard protocol, superiority or equivalence to antifungals, durable symptom relief, recurrence prevention, or benefit important to patients. Denture stomatitis is a specific clinical setting; the results do not transfer to general oral thrush, intestinal or whole-body Candida explanations, or a consumer product described as a biofilm disruptor.
Limitations
The paper has an unresolved participant-count discrepancy: 450 in the Results section versus 460 in the abstract. Trials were small and differed in denture-stomatitis severity, antifungal regimens, PDT photosensitizers and light parameters, session schedules, outcome measures, and follow-up. Heterogeneity was substantial in several pools, including I²=85% for day-15 PDT-alone mycological results and I²=72% and 97% for the two adjunct comparisons. Five trials were rated low risk of bias, three high, and three unclear; randomization and masking were frequent weaknesses. Only two trials were pooled for each adjunct comparison, and no interpretable CFU unit is identified in the forest plot. The review reported no adverse-event results, pooled adverse outcomes, withdrawals, or missing-outcome counts. It therefore cannot show that adverse events were absent. The later review's borderline standardized day-15 result uses the same apparent two trials, has very-low certainty and high heterogeneity, provides no group Ns, contains an unresolved citation mismatch for an “Alves 2020” row, and does not explain its all-time handling of repeated follow-up observations.
Contribution to the evidence
Contextual. S253 provides a broader 11-trial historical inventory with arm-level counts and forest-plot data, a clinical-sign analysis, and explicit trial risk-of-bias ratings. It is not the current synthesis. The later review changes how the conflicting adjunct analyses should be described, but both analyses remain uncertain and do not change the linked evidence map's claim verdict, body-of-evidence level, safety status, or practical action.
Practical change
No practical change. The pooled results do not establish benefit from adding PDT, and this summary does not recommend PDT. These clinical trials do not support a consumer biofilm-disrupting product or a broader Candida explanation; treatment decisions remain within condition-specific dental or medical care.
Funding and conflicts
The 2024 authors reported that no funding was received and declared no competing interests. The 2026 comparison review's publisher record and full text do not report funding or competing interests; those disclosures should be treated as unreported, not as none.
Sources
Read the original 2024 publication (Al-Maweri et al., BMC Oral Health. 2024;24:84; published January 16, 2024; full text). For current-evidence context, see the 2026 systematic review by Tongwichian and Kessuwanrak (Journal of The Department of Medical Services. 2026;51(2):22–30; published June 15, 2026). The later review's forest plot labels one study “Alves 2020,” but its reference 15 is a 2018 case report, so the exact identity of that plotted row remains unresolved.
Study type, population, and sample scale
- Study type
- PRISMA-guided systematic review and random-effects meta-analysis of randomized clinical trials
- Population
- Patients with denture stomatitis enrolled in randomized trials of photodynamic therapy alone or as an antifungal add-on; the review did not report one shared case definition or severity threshold.
- Sample scale
- 11 RCTs published from 2011 to 2023; Results text reports 450 participants and the abstract reports 460. Eight trials compared PDT alone with an antifungal; three evaluated an adjunct PDT arm; eight trials were pooled.
Results
- The review searched through June 7, 2023 and included 11 randomized trials (2011–2023). Its Results section says 450 participants, while the abstract says 460; the paper does not resolve the discrepancy. Eight trials compared PDT alone with a topical antifungal, three evaluated an adjunct PDT arm, and eight trials were quantitatively pooled.
- For PDT alone versus topical antifungal at day 15, five trials included 100 PDT and 103 antifungal participants; the pooled mean difference (MD) was 0.95 (95% CI −0.28 to 2.19; I²=85%; p=.13). At end of follow-up, six trials included 115 and 118 participants; MD was −0.17 (−1.33 to 0.98; p=.77). The figure gives I²=81%, while the Results text gives 88%.
- Across five trials, reported clinical-sign improvement was 57/103 with PDT and 54/108 with antifungal treatment (OR 1.28, 95% CI 0.72–2.29; I²=3%; p=.40). The review did not harmonize the trials' definitions of clinical improvement.
- For adjunct PDT plus antifungal versus antifungal alone, the two pooled trials included 48 participants per group. The day-15 MD was −6.67 (95% CI −15.15 to 1.82; I²=72%; p=.12); at end of follow-up it was −7.14 (−19.78 to 5.50; I²=97%; p=.27). The forest plot does not identify an interpretable CFU unit, so these values are reported without conversion.
- A later 2026 systematic review appears to reanalyze the same two adjunct trials with standardized mean differences (SMDs). It reports a borderline day-15 SMD of −1.350 (95% CI −2.689 to −0.101; p=.048; I²=88.2%), no day-60 effect (−1.007, −2.553 to 0.539; p=.202; I²=92.5%), and an all-time estimate of −1.173 (−1.990 to −0.356; p=.005; I²=86.3%). It rates certainty very low, gives no forest-plot group Ns, and does not explain how repeated follow-up observations were handled. The day-15 result is a different analysis of the same trials, not new participant evidence or established patient benefit.
Limitations
- The Results text reports 450 participants, but the abstract reports 460.
- The internal discrepancy is unresolved; neither total should be silently substituted for the other.
- Trial samples ranged from 22 to 65 and follow-up from 30 to 90 days, with different antifungals, PDT photosensitizers, light sources, parameters, sessions, and outcome measures.
- Heterogeneity was substantial for several pooled comparisons, including I²=85% for PDT-alone day-15 mycological results and I²=72% and 97% for adjunct results. The review could not conduct planned sensitivity or subgroup analyses.
- Five trials were rated low risk of bias, three high risk, and three unclear; randomization reporting and masking were frequent problems.
- Small trials and these methodological concerns limit confidence; the review did not establish superiority, equivalence, noninferiority, recurrence prevention, or a standardized protocol.
- The article reports no adverse-event result, pooled adverse outcome, withdrawal count, or missing-outcome count.
- The review authors' low-risk ratings for incomplete outcome data and selective reporting do not show that adverse events were assessed or absent.
- Only two trials contribute to each pooled adjunct comparison, and their forest-plot values have no interpretable CFU unit stated.
- The estimates are heterogeneous and imprecise. The later review uses standardized estimates for the same apparent two-trial subset, gives very-low GRADE certainty and no group Ns, has an unresolved Alves citation mismatch, and does not explain cross-time pooling; it does not establish adjunct benefit.
Applies to
- The 2024 review's randomized comparisons of clinician-delivered photodynamic therapy for diagnosed denture stomatitis and the outcomes reported in those trials.
- Historical context on PDT alone or PDT added to topical antifungal treatment in heterogeneous denture-stomatitis trials.
Does not apply to
- A consumer supplement, enzyme, or other marketed product described as a biofilm disruptor.
- Candida infection outside the denture-stomatitis setting, general oral thrush, intestinal or whole-body Candida claims, or recurrence prevention.
- A standard PDT protocol, superiority or equivalence to antifungals, adverse-event safety, or patient-important benefit established by the pooled estimates.
Contribution to the current conclusion
Contextual
This 2024 review adds a broad, arm-level account of randomized PDT trials for diagnosed denture stomatitis, including clinical-sign data and trial risk-of-bias ratings. It is a historical synthesis searched through June 2023, not the current pooled answer. A 2026 review of an overlapping two-trial adjunct subset reports a different borderline day-15 standardized estimate, but its very-low GRADE certainty, high heterogeneity, citation mismatch, and unexplained pooling across repeated follow-up measurements leave the adjunct result unresolved. Neither review changes practical action or supports a consumer biofilm product.
Related evidence mapPractical change or no change
No practical change. These reviews describe clinician-delivered PDT studied for diagnosed denture stomatitis; their uncertain and heterogeneous estimates do not justify recommending PDT, a consumer biofilm product, or a change to antifungal care.
Funding and conflicts
- Funding
- The authors reported that no funding was received for this study.
- Conflicts
- The authors declared no competing interests.
- Paper date
- 2024-01-16
Sources
View all 2 sources
- Efficacy of photodynamic therapy on candida colonization and clinical symptoms in denture stomatitis: a systematic review and meta-analysis
- Source type
- Systematic review
- Published
- 2024-01-16
- Effectiveness of Photodynamic Therapy and Antifungal Medication in Treating Denture Stomatitis: A Systematic Review and Meta-analysis
- Source type
- Systematic review
- Published
- 2026-06-15